T1	Participants 115 157	venous thromboembolism in cancer patients.
T2	Participants 164 200	patients with venous thromboembolism
T3	Participants 437 523	patients on long-term therapy for acute venous thromboembolism who have active cancer.
T4	Participants 524 594	Consecutive consenting patients from one center in a multicenter trial
T5	Participants 959 993	24 patients who had anti-Xa levels
T6	Participants 1285 1312	patients with active cancer
